SU5416 in Treating Patients With Advanced, Metastatic, or Recurrent Soft Tissue Sarcomas

Phase 2 Completed 60 enrolled National Cancer Institute (NCI)

NaSingle-groupOpen-labelTreatment

Summary

Phase II trial to study the effectiveness of SU5416 in treating patients who have advanced, metastatic, or recurrent soft tissue sarcomas. SU5416 may stop the growth of soft tissue sarcomas by stopping blood flow to the tumor.

Timeline

Start: 2000-10
Primary completion: 2004-07
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	semaxanib	Small molecule	—	Intravenous

SU5416 in Treating Patients With Advanced, Metastatic, or Recurrent Soft Tissue Sarcomas

Summary

Timeline

Drugs

Indications